Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer

S.H.I. Ou, S.M. Gadgeel, F. Barlesi, J.C.H. Yang, L. De Petris, D.W. Kim, R. Govindan, A.M. Dingemans, L. Crino, H. Lena, S. Popat, J.S. Ahn, E. Dansin, E. Mitry, B. Muller, W. Bordogna, B. Balas, P.N. Morcos, A.T. Shaw

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)22-27
Number of pages6
JournalLung Cancer
Volume139
DOIs
Publication statusPublished - 1 Jan 2020

Keywords

  • alectinib
  • alk
  • crizotinib
  • nsclc
  • overall survival
  • pooled analysis
  • safety
  • ALK
  • NSCLC
  • Pooled analysis
  • Alectinib
  • CRIZOTINIB
  • Safety
  • Overall survival

Cite this